scholarly journals Molecular characterization of extended-spectrum β-lactamases among clinical isolates of Escherichia coli & Klebsiella pneumoniae: A multi-centric study from tertiary care hospitals in India

2019 ◽  
Vol 149 (2) ◽  
pp. 208 ◽  
Author(s):  
Pallab Ray ◽  
Vikas Gautam ◽  
Anjana Thakur ◽  
Megha Sharma ◽  
Avinash Singh ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Klebsiella Pneumoniae ◽  
Molecular Characterization ◽  
Tertiary Care ◽  
Clinical Isolates ◽  
Extended Spectrum ◽  
Tertiary Care Hospitals

scholarly journals Molecular Characterization of Extended-Spectrum β-Lactamase–Producing Escherichia coli and Klebsiella pneumoniae Among the Pediatric Population in Qatar

2020 ◽  
Vol 11 ◽  
Author(s):  
Andres Perez-Lopez ◽  
Sathyavathi Sundararaju ◽  
Hassan Al-Mana ◽  
Kin Ming Tsui ◽  
Mohammad Rubayet Hasan ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Klebsiella Pneumoniae ◽  
Molecular Characterization ◽  
Pediatric Population ◽  
Extended Spectrum

scholarly journals Molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates from hospitals in Lithuania

2010 ◽  
Vol 59 (10) ◽  
pp. 1263-1265 ◽  
Author(s):  
Vaida Šeputienė ◽  
Marius Linkevičius ◽  
Aurelija Bogdaitė ◽  
Justas Povilonis ◽  
Rita Plančiūnienė ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Klebsiella Pneumoniae ◽  
Molecular Characterization ◽  
Extended Spectrum

scholarly journals Susceptibility ofKlebsiella pneumoniaeIsolates from Intra-Abdominal Infections and Molecular Characterization of Ertapenem-Resistant Isolates

2011 ◽  
Vol 55 (8) ◽  
pp. 3917-3921 ◽  
Author(s):  
Stephen P. Hawser ◽  
Samuel K. Bouchillon ◽  
Christine Lascols ◽  
Meredith Hackel ◽  
Daryl J. Hoban ◽  
...  
Keyword(s):  
Antimicrobial Resistance ◽  
Klebsiella Pneumoniae ◽  
Molecular Characterization ◽  
Clinical Isolates ◽  
Extended Spectrum ◽  
Clinical Breakpoints ◽  
Abdominal Infections

ABSTRACTA total of 2,841 clinical isolates ofKlebsiella pneumoniaefrom intra-abdominal infections worldwide were collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) during 2008 and 2009. Overall, 22.4% of isolates had extended-spectrum β-lactamases (ESBLs). The most active antibiotics among the 11 tested were imipenem, amikacin, and ertapenem, though even these, like all other comparators, were less consistently active against ESBL-positive isolates than against ESBL-negative isolates. Globally, 6.5% of isolates were ertapenem resistant based on the June 2010 clinical breakpoints published by the Clinical and Laboratory Standards Institute, with MICs of ≥1 μg/ml. Molecular characterization of 43 isolates with ertapenem MICs of ≥4 μg/ml showed that they variously produced CTX-M or SHV ESBLs combined with altered impermeability and/or had KPC (n= 28), OXA-48 (n= 3), or VIM (n= 1) carbapenemases. Further monitoring of ertapenem susceptibility and molecular characterization of ertapenem-resistant isolates are needed.

Sign in / Sign up

Export Citation Format

Share Document